Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

Ashish Sarraju, JingWei Li, Christopher P. Cannon, Tara Chang, Rajiv Agarwal, George Bakris, David M. Charytan, Dick de Zeeuw, Tom Greene, Hiddo J. L. Heerspink, Adeera Levin, Bruce Neal, Carol Pollock, David C. Wheeler, Yshai Yavin, Hong Zhang, Bernard Zinman, Vlado Perkovic, Meg Jardine, Kenneth W. Mahaffey*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)

Abstract

We aimed to assess the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy according to prior history of heart failure in the Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation (CREDENCE) trial. We found that participants with a prior history of heart failure at baseline (15%) were more likely to be older, female, white, have a history of atherosclerotic cardiovascular disease, and use diuretics and beta blockers (all P <.001), and that, compared with placebo, canagliflozin safely reduced renal and cardiovascular events with consistent effects in patients with and without a prior history of heart failure (all efficacy P interaction >.150). These results support the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy regardless of prior history of heart failure.

Original languageEnglish
Pages (from-to)141-148
Number of pages8
JournalAmerican Heart Journal
Volume233
DOIs
Publication statusPublished - Mar-2021

Cite this